Factor VLeiden and prothrombin G20210A gene polymorphisms in patients with coronary artery disease

Yonsei Medical Journal

Volumn 49, Issue 2, 2008, Pages 237-243

  Ercan, Bahadir ^a   Tamer, Lülüfer ^a   Sucu, Nehir ^a   Pekdemir, Hasan ^a   Çamsan, Ahmet ^a   Atik, Uǧur ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Coronary artery disease; Factor VLeiden; Prothrombin G20210A gene

Indexed keywords

ADENINE; APOLIPOPROTEIN A; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 5 LEIDEN; CHOLESTEROL; GUANINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTHROMBIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION;

AGED; CORONARY ARTERY DISEASE; FACTOR V; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN;

EID: 44649202315     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2008.49.2.237     Document Type: Article

References (39)

1. Zaman AG, Helft G, Worthley SG, Badimon JJ. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000;149:251-66.
2. Ardissino BY, Mannucci PM, Mertini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999;94:46-51.
3. Ridker PM. Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and hemostasis. Thromb Haemost 1997;78: 53-9.
4. Cushman M. Hemostatic risk factors for cardiovascular disease. In: Schechter GP, Hoffman R, Schrier SL, eds. Hematology. Washington. DC: American Society of Haematology; 1999.
5. Di Minno G, Grandone E, Margaglione M. Clinical relevance of polymorphic markers of arterial thrombosis. Thromb Haemost 1997;78:462-6.
6. Grant PJ. Polymorphisms of coagulation/fibrinolysis genes: gene environment interactions and vascular risk Prostaglandins Leukot Essent Fatty Acids 1997;57:473-7.
7. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997;78:523-6.
8. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
9. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
10. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997;98:353-5.
11. Kapur RK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol
12. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997;78:1426-9.
13. Arruda VR, Annichino-Bizzacchi JM, Gonçalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430-3.
14. Watzke HH, Schüttrumpf J, Graf S, Huber K, Panzer S. Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb Res 1997;87:521-6.
15. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998;91:3562-5.
16. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
17. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997;17:2418-22.
18. Corral J, Gonzalez-Conjero R, Lozano ML, Rivera J, Heras I, Vicente V. The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol 1997;99:304-7.
19. Longstreth WT Jr, Rosendaal FR, Siscovic DS, Vos HL, Schwartz SM, Psaty BM, et al. Risk of stroke in young women and two prothrombotic mutations: factor VLeiden and Prothrombin gene variant (G20210A). Stroke 1998;29:577-80.
20. März W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in a coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995;345:526.
21. Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996;239:221-6.
22. Rosendaal FK, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, et al. Factor VLeiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89:2817-21.
23. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996;125:265-9.
24. Ridker PM, Hennekens CH, Lindpaintner Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
25. Demarmels Biasiutti F, Merlo C, Furlan M, Sulzer I, Binder BR, Lämmle B. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis 1995;6:456-9.
26. Lerman A, Suwaidi JA, Velianou JL. L-Arginine: a novel therapy for coronary artery disease? Expert Opin Investig Drugs 1999;8:1785-93.
27. Ross R The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
28. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90: 2126.
29. Farmer JA, Gotto AM Jr. Dyslipidemia and other risk factors for coronary artery disease. In: Braunwa E, editor. Heart disease. A textbook of cardiovascular medicine. 5th ed. Philadelphia, PA: W.B. Saunders; 1997.
30. Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, et al. Synergistic effects of prothrombic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 1999; 93:2186-90.
31. Russo C, Girelli D, Olivieri O, Guarini P, Manzato F, Pizzolo F, et al. G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. Circulation 2001;103:243640.
32. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor VLeiden or prothrombin 20210A. Circulation 1998;97:1037-41.
33. Burzotta F, Paciaroni K, De Stefano V, Chiusolo P, Manzoli A, Casorelli I, et al. Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J 2002;23:26-30.
34. Makris TK, Krespi PC, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, Triposkiadis FK, et al. Resistance to activated protein C and FV Leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens 2000,13:61-5.
35. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999;99:999-1004.
36. Çelik S, Ovali E, Baykan M, Uçar F, Erdöl C, Durmuş I, et al. Factor VLeiden and its relation to left ventricular thrombus in acute myocardial infarction. Acta Cardiol 2001; 56:1-6.
37. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart study and 2 meta-analyses. Blood 2002;100:3-10.
38. Emmerich J, Poirier O, Evans A, Margues-Vidal P, Arveiler D, Luc G, et al. Myocardial infarction, Arg506 to G1n factor V mutation, and activated protein C resistance. Lancet 1995;345:321.
39. van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1995;1:185.